The Priority Review

Policy Brief

MindMaze Therapeutics secures up to CHF 4 million financing

MindMaze Therapeutics announced agreements for up to CHF 4 million from long-term strategic investors, with CHF 3 million scheduled for November and December 2026 and an option for an additional CHF 1 million until February 28, 2027. The proceeds will support the wider commercial deployment of its neurotherapeutics platform and the launch of MindMotion Lite for home deployment.

Primary source

Company press release (PR Newswire), November 17, 2026

MindMaze Therapeutics Announces CHF 4 Million Financing

Read the source: MindMaze Therapeutics Announces CHF 4 Million Financing prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation